Coherus Oncology to Engage Investors at Major Conferences
In an effort to strengthen its engagement with the investment community, Coherus Oncology, Inc. (NASDAQ: CHRS) has announced its participation in several key investor conferences. These events will provide a platform for the company to showcase its innovative cancer treatments and discuss future developments.
Overview of Upcoming Conferences
The upcoming conferences are a significant opportunity for Coherus to connect with investors and present their developments in oncology. After a year of advancements, the company’s management will share insights into their latest projects, including their flagship PD-1 inhibitor, LOQTORZI. The presentations will be made available via webcasts, ensuring accessibility for a wider audience.
Highlighted Events
Coherus will conduct webcasts at the following distinguished conferences:
- UBS Global Healthcare Conference on November 10, which will take place at 1:15 p.m. Eastern Time.
- Jefferies Global Healthcare Conference scheduled for November 18 at 10:30 a.m. Greenwich Mean Time.
- Baird Biotech Discovery Series, taking place virtually on December 17 at 1:30 p.m. Eastern Time.
Accessing the Presentations
Investors interested in these webcasts can find links on the Investor Events section of Coherus’ website. The company plans to keep recordings of these presentations available for 30 days post-event, allowing attendees and interested parties ample time to access the information shared.
Networking Opportunities
One-on-one meetings with Coherus management can be arranged through bank representatives during the conferences. This offers investors a unique opportunity to discuss the company's strategy and competitive landscape directly with leadership.
Understanding Coherus Oncology
Coherus Oncology is on the cutting edge of treatment innovations, focused on developing and commercializing immunotherapeutic options for cancer care. With LOQTORZI being a critical player in their pipeline, the company is emphasizing its potential to treat various cancers, especially nasopharyngeal carcinoma.
In addition to LOQTORZI, Coherus is developing a diverse range of therapeutic candidates, including CHS-114, an antibody in Phase 1b/2a studies targeted at advanced solid tumors, and Casdozokitug, an IL-27 antagonistic antibody undergoing evaluations in several clinical trials. The commitment to advancing oncology is evident in their systematic approach to fostering synergistic combinations of their pipeline candidates.
The Pipeline and Future Directions
Coherus is dedicated to enhancing treatment effectiveness through innovative solutions that boost immune responses and improve patient outcomes. As more data emerges from ongoing clinical trials, the company aims to broaden the indications for its therapies, thus expanding its market presence.
Contact Coherus for More Information
As part of its commitment to transparency, Coherus uses its official website for material disclosures in compliance with regulatory obligations. Investors seeking further insight should visit the Coherus website or contact company representatives directly.
Investors can reach Jodi Sievers, VP of Investor Relations and Corporate Communications, via email at IR@coherus.com for any inquiries.
Frequently Asked Questions
What is Coherus Oncology's primary focus?
Coherus Oncology primarily focuses on developing innovative treatments for cancer, especially through immunotherapy.
Where can I access the upcoming presentations by Coherus?
The presentations will be available via webcasts on Coherus' Investor Events section of their website.
What products are highlighted in Coherus Oncology's pipeline?
Products like LOQTORZI and antibody candidates like CHS-114 and Casdozokitug are significant parts of their pipeline.
How can investors arrange a meeting with Coherus management?
Investors can request one-on-one meetings through their respective bank representatives during the conferences.
What is the significance of the upcoming conferences for Coherus?
These conferences are vital for Coherus to engage with investors and share strategic insights about their oncology advancements and pipeline developments.
